SK bioscience said it integrated an AI-based IT optimization system named ADO (AI-based Design Space Optimization System), developed in collaboration with DX Lab, the digital transformation unit of SK Discovery, into its vaccine research and development processes. 

ADO, developed over 18 months, utilizes AI to analyze data and predict success rates in the design of experiment (DoE) processes. This system aims to improve accuracy by predicting various process design variables that are typically challenging for researchers to analyze manually.

As a result, it reduces the number of experimental iterations, shortens development timelines, and lowers research costs.

The company has already confirmed promising results during the initial application of ADO in the protein conjugate vaccine development process.

The proof of concept (POC) demonstrated that ADO could reduce the experimental design period to one-third of the usual time.

This reduction is particularly beneficial for conjugate vaccines, which involve the complex task of binding polysaccharide molecules to carrier proteins.

By using ADO to predict and control these variables, the company expects to enhance the efficiency and success rate of the development process.

SK bioscience plans to expand the application of ADO beyond protein conjugation to various other experimental and production processes.

In addition to improving internal processes, SK bioscience sees potential commercial opportunities for ADO.

"By establishing a cutting-edge digital environment, we aim to secure global competitiveness," said Hwang Jae-seon, head of SK bioscience's Digital Innovation Department.